Trexquant Investment LP Purchases 89,544 Shares of Harrow, Inc. (NASDAQ:HROW)

Trexquant Investment LP boosted its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 1,806.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 94,500 shares of the company's stock after buying an additional 89,544 shares during the period. Trexquant Investment LP owned 0.27% of Harrow worth $3,170,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. AlphaQuest LLC grew its position in shares of Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after purchasing an additional 2,889 shares in the last quarter. Virtu Financial LLC purchased a new stake in Harrow during the 3rd quarter valued at approximately $271,000. Maridea Wealth Management LLC bought a new stake in shares of Harrow during the fourth quarter valued at approximately $222,000. KLP Kapitalforvaltning AS purchased a new position in shares of Harrow in the fourth quarter worth $235,000. Finally, Principal Financial Group Inc. purchased a new position in shares of Harrow in the third quarter worth $329,000. 72.76% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. B. Riley dropped their price target on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and set a $57.00 price objective on shares of Harrow in a report on Monday, March 31st.

Harrow Trading Up 2.6 %

Shares of NASDAQ:HROW traded up $0.61 during trading on Friday, reaching $24.09. The company's stock had a trading volume of 254,893 shares, compared to its average volume of 509,642. The firm's 50 day simple moving average is $26.87 and its two-hundred day simple moving average is $36.35. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 12 month low of $9.86 and a 12 month high of $59.23. The stock has a market capitalization of $858.90 million, a PE ratio of -25.63 and a beta of 0.46.

Harrow (NASDAQ:HROW - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.14. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The firm had revenue of $66.83 million during the quarter, compared to analysts' expectations of $66.01 million. On average, research analysts predict that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.